BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 31404615)

  • 21. Antibiotic tigecycline inhibits cell proliferation, migration and invasion via down-regulating CCNE2 in pancreatic ductal adenocarcinoma.
    Yang J; Dong Z; Ren A; Fu G; Zhang K; Li C; Wang X; Cui H
    J Cell Mol Med; 2020 Apr; 24(7):4245-4260. PubMed ID: 32141702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer.
    Totiger TM; Srinivasan S; Jala VR; Lamichhane P; Dosch AR; Gaidarski AA; Joshi C; Rangappa S; Castellanos J; Vemula PK; Chen X; Kwon D; Kashikar N; VanSaun M; Merchant NB; Nagathihalli NS
    Mol Cancer Ther; 2019 Feb; 18(2):301-311. PubMed ID: 30404927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion.
    O'Reilly EM; Hechtman JF
    Ann Oncol; 2019 Nov; 30(Suppl_8):viii36-viii40. PubMed ID: 31605106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extracellular lumican augments cytotoxicity of chemotherapy in pancreatic ductal adenocarcinoma cells via autophagy inhibition.
    Li X; Roife D; Kang Y; Dai B; Pratt M; Fleming JB
    Oncogene; 2016 Sep; 35(37):4881-90. PubMed ID: 26876211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice.
    Jiang SH; Li J; Dong FY; Yang JY; Liu DJ; Yang XM; Wang YH; Yang MW; Fu XL; Zhang XX; Li Q; Pang XF; Huo YM; Li J; Zhang JF; Lee HY; Lee SJ; Qin WX; Gu JR; Sun YW; Zhang ZG
    Gastroenterology; 2017 Jul; 153(1):277-291.e19. PubMed ID: 28315323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paraoxonase 2 Facilitates Pancreatic Cancer Growth and Metastasis by Stimulating GLUT1-Mediated Glucose Transport.
    Nagarajan A; Dogra SK; Sun L; Gandotra N; Ho T; Cai G; Cline G; Kumar P; Cowles RA; Wajapeyee N
    Mol Cell; 2017 Aug; 67(4):685-701.e6. PubMed ID: 28803777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine.
    Yeo D; He H; Patel O; Lowy AM; Baldwin GS; Nikfarjam M
    BMC Cancer; 2016 Jan; 16():24. PubMed ID: 26774265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer.
    Lu P; Geng J; Zhang L; Wang Y; Niu N; Fang Y; Liu F; Shi J; Zhang ZG; Sun YW; Wang LW; Tang Y; Xue J
    Oncogene; 2019 May; 38(20):3932-3945. PubMed ID: 30692639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma.
    Cheng K; Zhou Z; Chen Q; Chen Z; Cai Y; Cai H; Wu S; Gao P; Cai Y; Zhou J; Wang X; Wu Z; Peng B
    Sci Rep; 2024 Apr; 14(1):8389. PubMed ID: 38600093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.
    Sahu N; Chan E; Chu F; Pham T; Koeppen H; Forrest W; Merchant M; Settleman J
    Mol Cancer Ther; 2017 Sep; 16(9):1729-1738. PubMed ID: 28619758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.
    Wang C; Liu P; Wu H; Cui P; Li Y; Liu Y; Liu Z; Gou S
    Oncotarget; 2016 Mar; 7(12):14912-24. PubMed ID: 26908446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma.
    Grbovic-Huezo O; Pitter KL; Lecomte N; Saglimbeni J; Askan G; Holm M; Melchor JP; Chandwani R; Joshi S; Haglund C; Iacobuzio-Donahue CA; Chiosis G; Tammela T; Leach SD
    Proc Natl Acad Sci U S A; 2020 Dec; 117(48):30670-30678. PubMed ID: 33199632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of cell death in pancreatic ductal adenocarcinoma by indirubin 3'-oxime and 5-methoxyindirubin 3'-oxime in vitro and in vivo.
    Sano M; Ichimaru Y; Kurita M; Hayashi E; Homma T; Saito H; Masuda S; Nemoto N; Hemmi A; Suzuki T; Miyairi S; Hao H
    Cancer Lett; 2017 Jul; 397():72-82. PubMed ID: 28347789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metformin suppresses the invasive ability of pancreatic cancer cells by blocking autocrine TGF‑β1 signaling.
    Duan W; Qian W; Zhou C; Cao J; Qin T; Xiao Y; Cheng L; Li J; Chen K; Li X; Ma J; Ma Q
    Oncol Rep; 2018 Sep; 40(3):1495-1502. PubMed ID: 29956804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC.
    Brown M; Zhang W; Yan D; Kenath R; Le L; Wang H; Delitto D; Ostrov D; Robertson K; Liu C; Pham K
    PLoS One; 2020; 15(1):e0226917. PubMed ID: 31929540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer-Specific Targeting of Taurine-Upregulated Gene 1 Enhances the Effects of Chemotherapy in Pancreatic Cancer.
    Tasaki Y; Suzuki M; Katsushima K; Shinjo K; Iijima K; Murofushi Y; Naiki-Ito A; Hayashi K; Qiu C; Takahashi A; Tanaka Y; Kawaguchi T; Sugawara M; Kataoka T; Naito M; Miyata K; Kataoka K; Noda T; Gao W; Kataoka H; Takahashi S; Kimura K; Kondo Y
    Cancer Res; 2021 Apr; 81(7):1654-1666. PubMed ID: 33648930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
    Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
    Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism.
    Du J; Wang X; Li Y; Ren X; Zhou Y; Hu W; Zhou C; Jing Q; Yang C; Wang L; Li H; Fang L; Zhou Y; Tong X; Wang Y
    Cell Death Dis; 2021 Jul; 12(7):705. PubMed ID: 34262021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disulfiram Synergizes with SRC Inhibitors to Suppress the Growth of Pancreatic Ductal Adenocarcinoma Cells in Vitro and in Vivo.
    Li Z; Xie X; Tan G; Xie F; Liu N; Li W; Sun X
    Biol Pharm Bull; 2021; 44(9):1323-1331. PubMed ID: 34471060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.